Pediatric Tumor Lysis Syndrome
Betsy Bickert, Anne F. Reilly
Abstract
Betsy Bickert, Anne F. Reilly
Abstract
Patients with a high tumor burden may develop tumor lysis syndrome. Tumor lysis syndrome consists of at least 2 metabolic abnormalities, which may include hyperkalemia, hyperphosphatemia, or hyperuricemia. The goal of standard therapy is to prevent tumor lysis syndrome. Prophylactic therapy includes hydration, alkalinization, and treatment to lower uric acid with either allopurinol or rasburicase. Other metabolic abnormalities are treated as they occur.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Patients with a high tumor burden may develop tumor lysis syndrome. Tumor lysis syndrome consists of at least 2 metabolic abnormalities, which may include hyperkalemia, hyperphosphatemia, or hyperuricemia. The goal of standard therapy is to prevent tumor lysis syndrome. Prophylactic therapy includes hydration, alkalinization, and treatment to lower uric acid with either allopurinol or rasburicase. Other metabolic abnormalities are treated as they occur.
Key concepts: Tumor lysis syndrome, Rasburicase, Hyperphosphatemia, Hyperuricemia, Medicine, Hyperkalemia, Allopurinol, Lysis